top of page

In The News

Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways

ScienceDirect.com 

April 2024

​

Psilocybin eases burnout and depression, UW study finds

Axios.com

Dec 5, 2024

 

US soldiers to be given ecstasy drug in PTSD trial

TheTimes.com

March 21 2025

 

MDMA’s Latest Trial Results Offer Hope for Patients with PTSD

UCSF

September 18, 2023

​

Can An Experimental Drug Rewire the Brain to Treat Parkinson’s?

Columbia University

November 26, 2024

​

Silo Pharma Plans Phase 2B Trial Testing Low-dose Psychedelics in Parkinson’s

ParkinsonsNewsToday.com

December 4, 2020

​

Looking Into Psychedelics for Alzheimer's Research

BrainFacts.org

13 Dec 2022

​

Far Out: New Psychedelic for Alzheimer’s Depression Heads to Trials

Being Patient.com

September 20th, 2022

Bein

Ground-breaking LSD Microdosing for Alzheimer’s Study

The Beckley Foundation

2025

 

Phase 2 Study of COMP360 Psilocybin Finds Improved PTSD Symptoms

Psychiatric Times

May 9, 2024

 

Medical Uses and Adverse Effects of Psilocybin

Psychiatrist.com  

May 28, 2024
 

The Role of Set and Setting in Psilocybin Therapy for Trauma

Changa Institute

Jan 16, 2025

​​

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis

Science Direct  

May 2024

​

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Nature Medicine  

September 14, 2023

​

Psilocybin for Trauma-Related Disorders

National Institute of Health

2022

​

Psilocybin Spurs Brain Activity in Patients With Depression, Small Study Shows

The New York Times 

APRIL 11, 2022

​​

​​

Microdosed LSD: Finally A Breakthrough For Alzheimer’s Disease?

Forbes

Feb 21, 2020

bottom of page